Biochemical markers and skeletal metastases

Area of Science:

• Oncology
• Biochemistry
• Orthopedics

Background:

• Skeletal metastases are common in breast, prostate, and lung cancers.
• Diagnosing and monitoring bone metastases nonradiologically remains challenging.
• Biochemical markers of bone remodeling show promise for managing metastatic bone disease.

Purpose of the Study:

• To evaluate the utility of bone remodeling markers in patients with metastatic bone disease.
• To correlate marker levels with the presence and extent of skeletal involvement.
• To assess the potential of these markers in guiding treatment decisions.

Main Methods:

• Measured serum levels of bone specific alkaline phosphatase (BAP) and carboxyterminal telopeptide of Type I collagen (ICTP).
• Measured urine levels of pyridinoline (PYD), deoxypridinoline (DPD), and N-telopeptide (NTx).
• Correlated marker levels with bone scan-documented metastases, disease extent, and lesion type (blastic/lytic).

Main Results:

• All measured bone markers were elevated in patients with bone metastases.
• Urine NTx and serum BAP levels significantly correlated with the number of skeletal sites involved.
• Both markers were higher in blastic lesions compared to osteolytic lesions.

Conclusions:

• Biochemical markers of bone resorption and formation are elevated in metastatic bone disease.
• N-telopeptide (NTx) and bone specific alkaline phosphatase (BAP) are useful for assessing and managing bone metastases.
• These markers correlate with disease presence and extent, aiding treatment guidance and monitoring therapy effectiveness.